Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.
Ritter
J
J
AML-BFM Study Group, University Children's Hospital, Münster, FRG.
Creutzig
U
U
Schellong
G
G
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005860:Germany, West / Q000453:epidemiology; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000145:classification / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D015993:Life Tables; D015337:Multicenter Studies as Topic; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage
D003561:Cytarabine; D005047:Etoposide; D004317:Doxorubicin; D013866:Thioguanine; D003630:Daunorubicin